

## **Product datasheet for DA3517**

## VEGF-E (ov-HB) Orf Virus Protein

**Product data:** 

**Product Type:** Recombinant Proteins

**Description:** VEGF-E (ov-HB) orf virus protein, 5 μg

Species: Orf Virus
Expression Host: Insect
Predicted MW: 44 kDa

**Purity:** >90% pure by SDS-PAGE and visualised by silver stain

**Buffer:** Presentation State: Purified

State: Lyophilized purified protein

Buffer System: 50 mM Acetic Acid, without stabilizer

**Bioactivity:** Biological: Measured by its ability to stimulate 3H-thymidine incorporation in human

macrovascular (HUVE) and microvascular (HDME) endothelial cells. The ED50 for this effect is

typically 5-20 ng/ml. Range: 1-30 ng/ml.

**Endotoxin:** < 0.1 ng per µg of VEGF-E

**Reconstitution Method:** The lyophilised HB-VEGF-E is soluble in water and most aqueous buffers.

The lyophilised HB-VEGF-E should be reconstituted in PBS or medium containing at least 0.1%

Human or Bovine Serum Albumin to a concentration not lower than 50 μg/ml.

**Preparation:** Lyophilized purified protein

**Protein Description:** A DNA sequence encoding the first 116 amino acid residue of Orf virus VEGF-E isolate D1701

(Dehio et al., 1999 EMBO J. 18:363-374; GenBank accession No. AF106020) was fused with a DNA sequence encoding to the C-terminal heparin binding domain of human VEGF<sub>165</sub>. The

chimeric protein was expressed in insect cells using a baculovirus expression system.

Storage: Store lyophilized at 2-8°C for 6 months or at -20°C long term.

After reconstitution store the antibody undiluted at 2-8°C for one month

or (in aliquots) at -20°C long term. Avoid repeated freezing and thawing.

**Stability:** Shelf life: one year from despatch.



**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com



Summary:

Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994 J. Virol 68:84-92). Different isolates of orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appear to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999 EMBO J. 18:363-374; Wise et al., 1999 Proc. Natl. Acad. Sci USA 96:3071-3076). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E and hb-VEGF-E can not bind to VEGF receptor-1 (Flt-1). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor-2/ KDR. Compared to human VEGF165 this virus form has no heparin-binding domain and seems to be a freely secreted protein comparable to VEGF121. In order to compare this form with human VEGF165, an additional heparin-binding domain was engineered at the C-terminus to allow interaction with proteo-aminoglycans and heparan sulfate. These form is also able to interact with neuropillin-1.

## **Product images:**

